UNSPSC 51112027: Cabozantinib

Cabozantinib is a medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.

UNSPSC 51112027 Cabozantinib, a Commodity code, shows no recent state and local procurement activity that aligns with the code's pharmaceutical scope. The recent opportunities block contains notices related to nursing department relocations, vendor networking forums, purchasing surveys, and pharmaceutical procurement solicitations for naloxone, drug deactivation systems, BLS/ALS supplies, drug reference standards, and generic multi-source pharmaceuticals through cooperative purchasing—none of which reference cabozantinib or oncology therapeutics specifically. One opportunity (Seminole County's naloxone and drug deactivation systems procurement via IFB60459723LAS with response due July 26, 2023) and another (Tucson Fire Department's BLS/ALS pharmaceuticals procurement via RFP260217 with response due June 24, 2026) involve pharmaceutical or drug-related products, but neither targets the tyrosine kinase inhibitor or cancer treatment market that cabozantinib serves.

State and local procurement activity under cabozantinib appears dormant. Recent pharmaceutical-related solicitations focus on emergency medical services supplies, forensic drug reference standards, naloxone distribution, and generic OTC products through cooperative wholesaler networks. No county health departments, state purchasing offices, or municipal agencies have posted solicitations for oncology medications or cabozantinib in particular. The code's activity does not warrant active pursuit at this time; monitor cooperative purchasing platforms and state pharmaceutical benefit manager solicitations for future cancer therapeutic opportunities.